News

Pain Therapeutics’ PTI-125, Potential Treatment for Alzheimer’s, to Undergo Phase 1 Clinical Trial

Pain Therapeutics will soon launch a Phase 1 clinical trial to study the safety and efficacy of PTI-125 in treating Alzheimer’s disease. The announcement came after the U.S. Food and Drug Administration (FDA) accepted the company’s investigational new drug application for the therapy. It follows a recently awarded $1.7 million research grant by the…

Regenacy’s HDAC Blocker Improved Cognitive Function in Mice with Alzheimer’s, Study Shows

A compound that blocks the activity of so-called HDAC enzymes in the brain improved learning in mouse models of Alzheimer’s disease, according to data that Regenacy Pharmaceuticals presented at the recent 2017 Alzheimer’s Association International Conference (AAIC) July 16-20 in London. Regenacy’s RCY-1305 blocks the enzymes HDAC1 and HDAC2, which…

ARPF Includes Yoga, Meditation in New Brain Therapy Training Program to Prevent Alzheimer’s

The Alzheimer’s Research and Prevention Foundation (ARPF) will launch a new Brain Longevity Therapy Training Program to educate wellness and healthcare workers on the four pillars of Alzheimer’s disease prevention: diet, stress management, exercise and spiritual fitness. The spiritual fitness segment focuses on yoga and meditation techniques,…

Highlights of Alzheimer’s Event Include New Use of PET Scans, a Blood Test and a Protein Imaging Development

A plan to test a multi-dimensional, lifestyle-based approach to preventing cognitive decline and dementia in people at risk of Alzheimer’s was one of the important revelations that surfaced at the 2017 Alzheimer’s Association International Conference, experts said. Other convention highlights that the Alzheimer’s Association identified included: Interim results of a…